OPKO Health's (OPK) ModeX Therapeutics subsidiary launched phase 1 clinical trials for an Epstein-Barr virus vaccine candidate in partnership with Merck (MRK).
The first participant was dosed in the MDX2201 study, which will assess safety and tolerability in up to 200 healthy adults, ModeX said Tuesday in a statement, and this stage triggers an undisclosed cash milestone payment to ModeX from Merck.
The vaccine candidate targets multiple viral proteins to stimulate immunity against EBV, which causes infectious mononucleosis and is linked to various cancers and multiple sclerosis.
OPKO shares rose 4.1% in recent Tuesday trading, and Merck gained 2.7%.
Price: 1.51, Change: +0.06, Percent Change: +4.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。